Small and large molecule drug development often necessitates distinct analytical methodologies. Agilex has extensive experience de...
Agilex has extensive experience developing and validating like-binding assays for specific immune-oncology therapeutics. From a...
Come to Our EBF Session in Barcelona to Hear how Agilex Can Make Your PK Data SPARCL SPARCL stands for Spatial Proximity Analyt...
How do Australia's streamlined regulatory process and global tax incentive apply to your toxicology studies? There are many ben...
by Holly Stefl, Chief Commercial Officer It is with much enthusiasm that Agilex Biolabs introduces its newest Senior Developmen...
by Kurt Sales In the realm of bioanalytical research, immunoassays stand as a cornerstone technology, enabling the precise dete...
by Holly Stefl, Chief Commercial Officer Agilex Biolabs is proud to introduce the West Coast of the United States to their new...
by Dr. Kurt Sales, Chief Scientific Officer Pharmacokinetics is a key component in a drug development program in enabling us to...
by Dr. Kurt Sales, Chief Scientific Officer In the ever-evolving landscape of pharmaceuticals, advancements in science have led...
Dr. Kurt Sales Presents Groundbreaking Findings at WRIB Conference Recently Dr. Kurt Sales, the Chief Scientific Officer of Agi...
by Kurt Sales The rise of Cell and Gene Therapy products is increasingly becoming more prevalent. At Agilex we are seeing more...
Recent Report Shows Australia Rising to 3rd in Number of Industry-Initiated Phase I Clinical Trials in 2021 The Association of...
